MedCity News November 27, 2024
Marissa Plescia

Several healthcare leaders are supporting the Biden-Harris administration’s proposed rule to expand Medicare and Medicaid coverage of GLP-1 medications for obesity treatment.

Several healthcare leaders are showing their support for the Biden-Harris Administration’s new proposed rule that would expand coverage of GLP-1s for those with Medicare and Medicaid.

Medicare and Medicaid currently cover GLP-1s like Ozempic and Wegovy for diabetes, but Medicare is prohibited from covering them for weight loss while only 13 state Medicaid programs do. The proposal, meanwhile, aims to cover the drugs for obesity as well. According to a White House fact sheet, the proposal could support 3.4 million Medicare enrollees and reduce out-of-pocket costs for these medications by 95% for some beneficiaries. In addition, 4 million...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicaid, Medicare, Pharma / Biotech, Provider
Related Articles:
KFF Health News' 'What the Health?': New Year, New Congress, New Health Agenda
Federal mental health parity bill returns: 5 things to know
Health care is Newsom's biggest unfinished project: Trump complicates that task
Why FDA Commissioner Robert Califf is 'concerned' about the incoming administration
Senate report blasts PE ownership in healthcare: 10 things to know

Share This Article